Lipid peroxidation is enhanced in patients with systemic lupus erythematosus and is associated with arterial and renal disease manifestations

被引:203
|
作者
Frostegård, J
Svenungsson, E
Wu, RH
Gunnarsson, I
Lundberg, IE
Klareskog, L
Hörkko, S
Witztum, JL
机构
[1] Karolinska Univ Hosp, Dept Med, Ctr Infect Med, S-14186 Huddinge, Stockholm, Sweden
[2] Karolinska Univ Hosp, Dept Med, Ctr Metab & Endocrinol, S-14186 Huddinge, Stockholm, Sweden
[3] Karolinska Inst, Stockholm, Sweden
[4] Karolinska Univ Hosp, Ctr Mol Med, Solna, Sweden
[5] RDL Reference Lab, Los Angeles, CA USA
[6] Univ Oulu, Oulu, Finland
[7] Univ Calif San Diego, San Diego, CA 92103 USA
来源
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 01期
关键词
D O I
10.1002/art.20780
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Cardiovascular disease with premature atherosclerosis is common in patients with systemic lupus erythematosus (SLE). We previously identified elevated levels of oxidized low-density lipoprotein (OxLDL) together with elevated levels of autoantibodies related to OxLDL as risk factors for cardiovascular disease in female patients with SLE. Autoantibodies to OxLDL are common in SLE and cross-react with anticardiolipin antibodies (aCL). We therefore hypothesized that lipid peroxidation is enhanced in patients with SLE in general. Methods. One hundred forty-seven female patients with SLE and 60 age- and sex-matched controls were compared. A monoclonal antibody to oxidized phospholipids, EO6, was used to determine oxidation epitopes on LDL. Anti-OxLDL and autoantibodies to malondialdehyde (MDA)-modified LDL, cardiolipin, and oxidized aCL were determined by chemiluminescence technique. Results. As determined by binding of EO6, patients with SLE had a higher level of oxidized phospholipids on LDL (P = 0.005) compared with controls. The level of OxLDL (e.g., oxidized phospholipid/ apolipoprotein B) was associated with arterial disease (P = 0.006) and renal manifestations (P = 0.04). As reported previously, levels of aCL, autoantibodies to OxLDL, and autoantibodies to MDA-modified LDL were enhanced and were closely correlated in SLE. Anticardiolipin antibodies from these SLE patients recognized mainly oxidized forms of cardiolipin, indicating that antigenic epitopes on cardiolipin are related to lipid peroxidation in patients with SLE. Conclusion. In general, patients with SLE (particularly those with cardiovascular disease) had more oxidized epitopes on LDL compared with controls. Furthermore, aCL in these patients recognized epitopes generated during lipid peroxidation. Thus, "neo" self antigens on lipoproteins, generated during oxidation, are present in SLE and may be of importance for the development of premature cardiovascular disease and possibly also for other autoimmune phenomena observed in SLE.
引用
收藏
页码:192 / 200
页数:9
相关论文
共 50 条
  • [1] Lipid-peroxidation is enhanced in sle patients and associated with arterial and renal disease manifestations
    Frostegard, J
    Svenungsson, E
    Wu, R
    Gunnarsson, I
    Lundberg, I
    Klareskog, L
    Hörkkö, S
    Witztum, J
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (01) : 65 - 66
  • [2] A Role of Lipid-Peroxidation in Systemic Lupus Erythematosus-Associated Cardiovascular Disease
    Patrick, David
    van Beusecum, Justin
    Ormseth, Michelle
    Crofford, Leslie J.
    Davies, Sean
    Dikalov, Sergey
    Harrison, David
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [3] Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus
    Plasin-Rodriguez, Miguel Angel
    Patricio, Patricia
    Monteagudo, Joan
    Garcia-Criado, Angeles
    Cervera, Ricard
    Reverter, Joan Carles
    Espinosa, Gerard
    Tassies, Dolors
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2021, 52 (01) : 30 - 41
  • [4] Procoagulant microparticles are associated with arterial disease in patients with systemic lupus erythematosus
    Miguel Angel Plasín-Rodríguez
    Patricia Patricio
    Joan Monteagudo
    Angeles García-Criado
    Ricard Cervera
    Joan Carles Reverter
    Gerard Espinosa
    Dolors Tàssies
    [J]. Journal of Thrombosis and Thrombolysis, 2021, 52 : 30 - 41
  • [5] Cutaneous Manifestations Associated with Systemic Lupus Erythematosus Disease Activity
    Sowerby, L.
    O'Brien, E.
    Joseph, L.
    Bernatskyz, S.
    Nashi, E.
    Vinet, E.
    Clarke, A. E.
    Pineau, C. A.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2014, 134 (05) : 1487 - 1487
  • [6] Cutaneous Manifestations Associated with Systemic Lupus Erythematosus Disease Activity
    Sowerby, Laura
    O'Brien, Elizabeth
    Joseph, Lawrence
    Bematsky, Sasha
    Nashi, Emil
    Vinet, Evelyne
    Clarke, Ann
    Pineau, Christian
    [J]. JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 963 - 963
  • [7] Hyperuricemia in systemic lupus erythematosus: is it associated with the neuropsychiatric manifestations of the disease?
    Sheikh, Mahdi
    Movassaghi, Shafieh
    Khaledi, Mohammad
    Moghaddassi, Maryam
    [J]. REVISTA BRASILEIRA DE REUMATOLOGIA, 2016, 56 (06) : 471 - 477
  • [8] Renal manifestations of paediatric systemic lupus erythematosus
    Dowsett, Thomas
    Oni, Louise
    [J]. CURRENT OPINION IN PEDIATRICS, 2022, 34 (02) : 203 - 208
  • [9] Psychiatric manifestations in patients with dysautonomy associated with systemic lupus erythematosus
    Canas, C. A.
    Rincon-Hoyos, H. G.
    Izquierdo, J. H.
    Bonilla-Abadia, F.
    Arbelaez-Cortes, A.
    [J]. LUPUS, 2012, 21 (10) : 1128 - 1130
  • [10] Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients
    Yu, H.-H.
    Wang, L.-C.
    Lee, J.-H.
    Lee, C.-C.
    Yang, Y.-H.
    Chiang, B. -L.
    [J]. RHEUMATOLOGY, 2007, 46 (09) : 1492 - 1494